A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

Completed · Phase 1 · Has a placebo group

Conditions studied: Obesity, Overweight

In brief

The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.

Key facts

Study ID

NCT06824051

Run by

Eli Lilly and Company

People needed

120

Starts

2025-02-17

Expected to finish

2026-01-26

Last updated by the study team

2026-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a Body Mass Index (BMI)
• ≥30.0 kilograms per square meter (kg/m2), or
• ≥27.0 kg/m2 with comorbidities

You may not qualify if…

• Have type 1 diabetes, type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
• Have an unstable body weight within 90 days prior to screening
• Have acute or chronic hepatitis
• Are taking other medications or alternative remedies to manage weight loss

Where it is running

• Clinical Pharmacology of Miami — Miami, Florida, United States
• Axis — Dilworth, Minnesota, United States
• Ohio Clinical Trials — Columbus, Ohio, United States
• Endeavor Clinical Trials — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.